Biomimetic Nanoplatform for Targeted Glioblastoma Therapy via Concurrently Triggering GPX4/DHODH Mediated Ferroptosis - PubMed
4 hours ago
- #nanoplatform
- #glioblastoma
- #ferroptosis
- Glioblastoma multiforme (GBM) is an aggressive and lethal brain cancer requiring new therapies.
- Ferroptosis, a novel cell death mechanism, shows potential for GBM therapy but is limited by tumor defenses.
- A multifunctional nanoplatform, MHL@M, is developed to target GBM by triggering ferroptosis via GPX4 and DHODH inhibition.
- MHL@M features a GBM cell membrane coating for BBB penetration and tumor targeting.
- H-MnO2 in MHL@M consumes GSH in the tumor microenvironment, producing toxic •OH for chemodynamic therapy.
- Hemin and leflunomide in MHL@M synergistically downregulate GPX4 and inhibit DHODH to enhance ferroptosis.
- In vitro and in vivo studies confirm MHL@M's tumor-targeting, TME-responsive, and ferroptosis-activating capabilities.
- This study supports ferroptosis-based strategies for GBM treatment.